Everything below concerns Coordination complex. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-10. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in water | Free peptide differs from the complex |
| Typical storage | approx. −20 °C, desiccated | Protect from light and moisture |
| Primary purity method | RP-HPLC with MS | Confirms peptide identity |
| Copper assay | ICP-MS or AAS | Measured separately from peptide purity |
| Main degradation routes | Metal loss, hydrolysis, oxidation | Rate depends on pH and matrix |
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
==== Adherence ==== Poor compliance with medications and follow-up visits are a major reason for treatment failure and disease progression in glaucoma patients. Poor adherence could lead to increased complication rates, thus increasing the need for non-pharmacological interventions, including surgery. Patient education and communication must be ongoing to sustain successful treatment plans for this lifelong disease with no early symptoms.
=== Examining what occurs at the cellular level of NL. === Tissue Architecture in NL Lesions A lesion is a tissue that has been altered or injured. They can occur as wounds or, in the case of progressive NL, ulcers. The tissue architecture of NL is characterized by degeneration of collagen in the dermis and subcutaneous layers. The lesions exhibit granulomatous inflammation, palisading granulomas, and thickened blood vessels. Palisading granulomas are significant because they show an immune cell ring around degenerated tissue, commonly seen in autoimmune and chronic inflammatory diseases. Thickened blood vessels occur due to an accumulation of immune cells. Together, all these structural features indicate NL as a chronic, inflammatory response. Fibroblasts and endothelial cells are malfunctioning, and there is an imbalance in tissue homeostasis. Fibroblast and collagen remodeling Fibroblasts contribute to the formation of connective tissue, collagen, and elastin. Failure in fibroblasts causes skin to atrophy and degenerate. Increased uptake of GLUT-1 (a glucose transporter) is observed in NL cases. When up-regulated: glycolysis, oxidative stress, and fibroblast proliferation all increase. Despite the metabolic increase, fibroblasts in NL dysfunction. This suggests that in NL tissue decay and dysfunction are linked to both structural and immunological tissue components. The tissue is observed to have increased GLUT-1 and decreased pro-collagen mRNA. A predominance of Type 1 collagen is observed in PL.
== Decay and capture products == A 135Xe atom that does not capture a neutron undergoes beta decay to 135Cs, one of the 7 long-lived fission products, while a 135Xe that does capture a neutron becomes almost-stable 136Xe. The probability of capturing a neutron before decay varies with the neutron flux, which itself depends on the kind of reactor, fuel enrichment and power level; and the 135Cs / 136Xe ratio switches its predominant branch very near usual reactor conditions. Estimates of the proportion of 135Xe during steady-state reactor operation that captures a neutron include 90%, 39%–91% and "essentially all". For instance, in a (somewhat high) neutron flux of 1014 n·cm−2·s−1, the xenon cross section of σ = 2.65×10−18 cm2 (2.65×106 barn) would lead to a capture probability of 2.65×10−4 s−1, which corresponds to a half-life of about one hour. Compared to the 9.14 hour half-life of 135Xe, this nearly ten-to-one ratio means that under such conditions, essentially all 135Xe would capture a neutron before decay. But if the neutron flux is lowered to one-tenth of this value, like in CANDU reactors, the ratio would be 50-50, and half the 135Xe would decay to 135Cs before neutron capture. 136Xe from neutron capture ends up as part of the eventual stable fission xenon which also includes 134Xe, 132Xe, and 131Xe produced by fission and beta decay rather than neutron capture. Nuclei of 133Xe, 137Xe, and 135Xe that have not captured a neutron all beta decay to isotopes of caesium.
=== Toxic exposure === Multiple studies have attempted to study the relationship between toxic exposure and autism, despite limitations related to the measurement of toxic exposure the methods for which were often indirect and cross-sectional. Systematic reviews have been conducted for numerous toxins including air pollution, thimerosal, inorganic mercury, and levels of heavy metals in hair, nails, and bodily fluids. Environmental exposure to inorganic mercury may be associated with higher autism risk, with high levels of mercury in the body being a valid disease-causing agent for autism. Significant evidence has not been found of an association between autism and the concentration of copper, cadmium, selenium, and chromium in the hair, nails, and bodily fluids. Levels of lead were found to be significantly higher in individuals with autism. The precision and consistency of results were not maintained across studies and were influenced by an outlier study. The atypical eating behaviors of autistic children, along with habitual mouthing and pica, make it hard to determine whether increased lead levels are a cause or a consequence of autism.
=== Isolation and the qualification drought (1963–1974) === The 1962 FIFA World Cup proved a false dawn. At the 1963 South American Championship in Bolivia, Colombia lost five of six matches and finished last of the seven competing nations with a single point, conceding nineteen goals in the thin air of La Paz and Cochabamba. Three successive qualifying campaigns followed the same pattern of narrow competence undone by a single heavy defeat. Colombia were beaten twice by Ecuador and thrashed 7–2 by Chile in the 1966 preliminaries, recovering only to win the return 2–0 once elimination was assured. Drawn with Brazil for Mexico 1970, they took a point from six matches against the eventual world champions and Paraguay combined, losing 6–2 in Rio de Janeiro. The 1974 campaign was the cruellest of the three. Under the Yugoslav coach Toza Veselinović, Colombia went unbeaten across four matches, drawing three and winning in Montevideo 1–0 through Willington Ortiz on 5 July 1973 — a result long remembered in Colombia as a rare reverse for Uruguay at home. Colombia finished level with Uruguay on five points but were eliminated on goal difference.
Sources: en.wikipedia.org
=== Discovery === The word "benzene" derives from "gum benzoin" (benzoin resin), an aromatic resin known since ancient times in Southeast Asia, and later to European pharmacists and perfumers in the 16th century via trade routes. An acidic material was derived from benzoin by sublimation, and named "flowers of benzoin", or benzoic acid. The hydrocarbon derived from benzoic acid thus acquired the names benzin, benzol, and benzene. Michael Faraday first isolated and identified benzene in 1825 from the oily residue derived from the production of illuminating gas, giving it the name bicarburet of hydrogen. In 1833, Eilhard Mitscherlich produced it by distilling benzoic acid (from gum benzoin) and lime. He gave the compound the name benzin. In 1836, the French chemist Auguste Laurent named the substance "phène"; this word has become the root of the English word "phenol", which is hydroxylated benzene, and "phenyl", the radical formed by abstraction of a hydrogen atom from benzene. In 1845, Charles Blachford Mansfield, working under August Wilhelm von Hofmann, isolated benzene from coal tar. Four years later, Mansfield began the first industrial-scale production of benzene, based on the coal-tar method. Gradually, the sense developed among chemists that a number of substances were chemically related to benzene, comprising a diverse chemical family. In 1855, Hofmann was the first to apply the word "aromatic" to designate this family relationship, after a characteristic property of many of its members. In 1997, benzene was detected in deep space.
Meropenem solutions should not be frozen. Somewhat paradoxically, while meropenem is designed to resist bacterial enzymes, it can still be broken down by water. Specifically, the amide bond in the β-lactam ring of meropenem makes it resistant to many β-lactamases (penicillinases), which are bacterial enzymes that can break down penicillin and related antibiotics such as meropenem. Meropenem’s resistance is due to the stability of the β-lactam ring, which is less susceptible to hydrolysis by these enzymes. However, meropenem can undergo hydrolysis in aqueous solutions, which can reduce its effectiveness. Hence meropenem requires prolonged slow administration, or frequent re-administration, to continually replace what has been hydrolyzed by the water component of blood. Meropenem is administered every 8 hours. Dosing must be adjusted for altered kidney function and for haemofiltration. Studies describe application of meropenem therapeutic drug monitoring (measurements of drug levels in the bloodstream at specific intervals) for optimal application. As with other β-lactams antibiotics, the effectiveness of treatment depends on the amount of time during the dosing interval that the meropenem concentration is above the minimum inhibitory concentration for the bacteria causing the infection. For β-lactams, including meropenem, prolonged intravenous administration is associated with lower mortality compared to bolus intravenous infusion, especially in severe infections or those caused by less sensitive bacteria, such as Pseudomonas aeruginosa.
== Structures == The following illustrates the structures and abbreviations of the 21 amino acids that are directly encoded for protein synthesis by the genetic code of eukaryotes. The structures given below are standard chemical structures, not the typical zwitterion forms that exist in aqueous solutions.
== Other animals == Degenerative disc disease can occur in other mammals besides humans. It is a common problem in several dog breeds, such as the Dachshund, and attempts to remove this disease from dog populations have led to several hybrid breeds, such as the Chiweenie.
In 1992, Eric Taub brought ibogaine to an offshore location close to the United States, where he began providing treatments and popularizing its use. In Costa Rica, Lex Kogan, another leading proponent, joined Taub in systematizing its administration. The two men established medically monitored treatment clinics in several countries. In 1981, an unnamed European manufacturer produced 44 kg of iboga extract. The entire stock was purchased by Carl Waltenburg, who distributed it under the name "Indra extract" and used it in 1982 to treat heroin addicts in the community of Christiania, Copenhagen. Indra extract was available for sale over the Internet until 2006, when the Indra web presence disappeared. Various products are currently sold in several countries as "Indra extract", but it is unclear if any of them are derived from Waltenburg's original stock. Ibogaine and related indole compounds are susceptible to oxidation over time. The National Institute on Drug Abuse (NIDA) began funding clinical studies of ibogaine in the United States in the early 1990s, including conducting a clinical study in 1993, but terminated the project in 1995 following the unexpected death of a female participant. Data demonstrating ibogaine's efficacy in attenuating opioid withdrawal in drug-dependent human subjects was published by Alper et al. in 1999. A cohort of 33 patients were treated with 6 to 29 mg/kg of ibogaine; 25 displayed resolution of the signs of opioid withdrawal from 24 hours to 72 hours post-treatment, but one 24-year-old female, who received the highest dosage, died.
Sources: en.wikipedia.org
The colour comes from electronic transitions in the coordinated copper(II) ion. Ligand field effects absorb part of the visible spectrum. A colourless or greenish sample may indicate degraded material.
Copper can be displaced by other metal ions, by strong chelating agents, or by low pH. Samples exposed to these conditions may contain a mixture of free peptide and complex. Analytical testing is the only reliable way to confirm the bound fraction.
Solution storage generally shortens shelf life compared with the dry powder. Hydrolysis and oxidation proceed faster in aqueous media. Where solutions are used, cold storage and short holding times reduce measurable change.
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.